Skip to content

Tesamorelin

FDA-Approved• Prescribable
peptideInjection

FDA-approved GH booster for reducing visceral belly fat in HIV-associated lipodystrophy. Trials showed ~15-18% visceral fat reduction. Overall weight loss is modest vs GLP-1 agonists.

Key Facts

  • Classification
    Tesamorelin is a 44-amino acid GHRH analog with trans-3-hexenoic acid modification.
  • Primary Benefits
    Fat Loss (8/10) · Muscle Growth (6/10) · Longevity (4/10)
  • Administration
    Injection
  • Typical Dose
    2 mg subq daily, preferably before bed. Cycle for 12-26 weeks.
  • Evidence Strength
    Strong — 20 peer-reviewed studies referenced · Community sentiment 9/10
  • Stacks Well With
    AOD-9604, Ipamorelin
  • Legal Status
    FDA-Approved · prescription required · WADA prohibited

Quick Facts

From price
$35
Type
peptide
Administration
Injection
Evidence
strong
Studies referenced
20
Community sentiment
9/10
Stacks with
2 peptides
Regulatory
FDA-Approved

Top benefits

🔥 Fat Loss
8/10
💪 Muscle Growth
6/10
⏳ Longevity
4/10
View PricingCompare
1

Week 1–2

Subtle changes in body composition beginning. Improved sleep quality. Mild injection site reactions common. GH/IGF-1 levels starting to rise.

2

Week 3–6

Measurable reduction in visceral adipose tissue. Improved lipid panel markers. Better body composition visible. Enhanced recovery from physical activity.

3

Week 8+

Significant visceral fat reduction (15%+ in clinical trials). Improved triglyceride and cholesterol levels. Sustained GH optimization without insulin resistance.

Common Side Effects

Injection site reactions (erythema, pruritus)Joint pain (arthralgia)Peripheral edemaMuscle painParesthesia
Tolerance: Minimal — FDA-approved for long-term use in lipodystrophy
Cycling: 26-week cycles with monitoring. Can be used long-term under medical supervision. Monitor IGF-1 levels.

Scientific Overview

Tesamorelin is a 44-amino acid GHRH analog with trans-3-hexenoic acid modification. FDA-approved for HIV-associated lipodystrophy with ~15% trunk fat reduction and improved lipid profiles. Maintains physiological GH pulsatility without GH-associated insulin resistance.

Dosing

2 mg subq daily, preferably before bed. Cycle for 12-26 weeks.

Reconstitution, storage, injection sites & timing

Benefit Profile

🔥 Fat Loss
8/10
💪 Muscle Growth
6/10
⏳ Longevity
4/10
😴 Sleep
3/10
Medical oversight requiredNot safe during pregnancy· 4 contraindications